Premium
Optimizing Revascularization Strategies in Coronary Artery Disease for Optimal Benefit to Patients
Author(s) -
Mangiacapra F,
De Bruyne B,
Wijns W,
Bartunek J
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.162
Subject(s) - medicine , percutaneous coronary intervention , revascularization , conventional pci , coronary artery disease , cardiology , bypass grafting , myocardial revascularization , artery , myocardial infarction
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) have undergone substantial technological advances, and revascularization is an established therapeutic option in the treatment of coronary artery disease (CAD). Here we focus on optimization of decision making in revascularization strategies, as is being addressed in recent large clinical trials and the guidelines issued by the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS). Clinical Pharmacology & Therapeutics (2011) 90 4, 630–633. doi: 10.1038/clpt.2011.162